Generic placeholder image

Current Radiopharmaceuticals


ISSN (Print): 1874-4710
ISSN (Online): 1874-4729

Research Article

Physiological Animal Imaging with 68Ga-Citrate

Author(s): Ayşe Uğur and Aziz Gültekin*

Volume 14, Issue 1, 2021

Published on: 21 April, 2020

Page: [51 - 56] Pages: 6

DOI: 10.2174/1874471013666200421114031

Price: $65


Background: Gallium-68 is an ideal research and hospital-based PET radioisotope. The uptake mechanism of Gallium citrate is a combination of specific and non-specific processes, for example, vasodilatation, increased vascular permeability, plasma transferrin binding and lactoferrin and siderophores.

Objective: In this study, by applying the 68Ge/68Ga generator product, a simple technique for the synthesis and quality control of 68Ga-citrate was introduced and was followed by preliminary animal studies.

Methods: The synthesis of 68Ga-citrate was performed with a cationic method using the Scintomics automated synthesis system (Scintomics GmbH GRP module 4V). Since the standard procedure for quality control (QC) was not available, the definition of chemical and radiochemical purity of 68Ga-citrate was carried out according to the ICH Q2(R1) guideline. The standard QC tests were analysed with Scintomics 8100 radio-HPLC system equipped with a radioactivity detector. In this study, a New Zealand rabbit weighing 2520 g was used for PET/CT images.

Results: 68Ga-citrate synthesis was performed by a cationic method without using organic solvents. The labelling efficiency was found to be >98%. The HPLC method used to assess the radiochemical purity of 68Ga -citrate was validated as rapid, accurate and reproducible enough to apply it to patients safely. The physiological distribution of 68Ga-citrate was investigated in a healthy rabbit. The blood pool, liver, spleen, kidneys and growth plates were the most common sites of 68Ga-citrate involvement.

Keywords: Gallium, 68Gallium-citrate, PET/CT, 68Ga infection and inflammation imaging agents, radiolabelling, quality control, physiological distribution of 68Ga-citrate in rabbit.

Graphical Abstract
Vorster, M.; Maes, A.; Wiele, Cv.; Sathekge, M. Gallium-68 PET: A Powerful Generator-based Alternative to Infection and Inflammation Imaging. Semin. Nucl. Med., 2016, 46(5), 436-447.
[] [PMID: 27553469]
Lankinen, P.; Noponen, T.; Autio, A.; Luoto, P.; Frantzèn, J.; Löyttyniemi, E.; Hakanen, A.J.; Aro, H.T.; Roivainen, A. A Comparative 68Ga-Citrate and 68Ga-Chloride PET/CT Imaging of Staphylococcus aureus Osteomyelitis in the Rat Tibia. Contrast Media Mol. Imaging, 2018, 20189892604
[] [PMID: 29681785]
Berliner, C.; Tienken, M.; Frenzel, T.; Kobayashi, Y.; Helberg, A.; Kirchner, U.; Klutmann, S.; Beyersdorff, D.; Budäus, L.; Wester, H.J.; Mester, J.; Bannas, P. Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [68Ga]PSMA I&T and comparison with published data of [68Ga]PSMA HBED-CC. Eur. J. Nucl. Med. Mol. Imaging, 2017, 44(4), 670-677.
[] [PMID: 27896369]
Kumar, V.; Boddeti, D.K.; Evans, S.G.; Angelides, S. (68)Ga-Citrate-PET for diagnostic imaging of infection in rats and for intra-abdominal infection in a patient. Curr. Radiopharm., 2012, 5(1), 71-75.
[] [PMID: 22074481]
Aghanejad, A.; Jalilian, A.R.; Ardaneh, K.; Bolourinovin, F.; Yousefnia, H.; Samani, A.B. Preparation and Quality Control of (68)Ga-Citrate for PET Applications. Asia Ocean. J. Nucl. Med. Biol., 2015, 3(2), 99-106.
[PMID: 27408889]
Gültekin, A.; Üstün, F. Infection Models and Imaging Techniques Used in Preclinical Studies. Nucl Med Semin., 2019, 5, 59-68.
Kumar, V.; Boddeti, D.K. (68)Ga-radiopharmaceuticals for PET imaging of infection and inflammation. Recent Results Cancer Res., 2013, 194, 189-219.
[] [PMID: 22918761]
Vorster, M.; Buscombe, J.; Saad, Z.; Sathekge, M. Past and Future of Ga-citrate for Infection and Inflammation Imaging. Curr. Pharm. Des., 2018, 24(7), 787-794.
[] [PMID: 29189131]
Meyer, G-J.; Mäcke, H.; Schuhmacher, J.; Knapp, W.H.; Hofmann, M. 68Ga-labelled DOTA-derivatised peptide ligands. Eur. J. Nucl. Med. Mol. Imaging, 2004, 31(8), 1097-1104.
[] [PMID: 15029459]
Eppard, E.; Homann, T.; de la Fuente, A.; Essler, M.; Rösch, F. Optimization of Labeling PSMAHBED with Ethanol-Postprocessed 68Ga and Its Quality Control Systems. J. Nucl. Med., 2017, 58(3), 432-437.
[] [PMID: 28082433]
Schmuck, S.; Nordlohne, S.; von Klot, C.A.; Henkenberens, C.; Sohns, J.M.; Christiansen, H.; Wester, H.J.; Ross, T.L.; Bengel, F.M.; Derlin, T. Comparison of standard and delayed imaging to improve the detection rate of [68Ga]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer. Eur. J. Nucl. Med. Mol. Imaging, 2017, 44(6), 960-968.
[] [PMID: 28280856]
Salouti, M.; Fazli, A. Infectious Foci Imaging with Targeting Radiopharmaceuticals in Nuclear Medicine. INTECH, 2013, 9, 193-229.
Velikyan, I. 68Ga-Based radiopharmaceuticals: production and application relationship. Molecules, 2015, 20(7), 12913-12943.
[] [PMID: 26193247]
Taratonenkova, N.A.; Lyamtseva, E.A.; Malysheva, A.O. Quality Control Method for 111In-Oxine Radiopharmaceutical Composition. Pharm. Chem. J., 2019, 52(10), 868-872.
Bombardieri, E.; Aktolun, C.; Baum, R.P.; Bishof-Delaloye, A.; Buscombe, J.; Chatal, J.F.; Maffioli, L.; Moncayo, R.; Mortelmans, L.; Reske, S.N. 67Ga scintigraphy: procedure guidelines for tumour imaging. Eur. J. Nucl. Med. Mol. Imaging, 2003, 30(12), BP125-BP131.
[PMID: 14989225]
Xu, T.; Chen, Y. Research Progress of [(68)Ga]Citrate PET’s Utility in Infection and Inflammation Imaging: a Review. Mol. Imaging Biol., 2019.
[] [PMID: 31076971]
Rizzello, A.; Di Pierro, D.; Lodi, F.; Trespidi, S.; Cicoria, G.; Pancaldi, D.; Nanni, C.; Marengo, M.; Marzola, M.C.; Al-Nahhas, A.; Rubello, D.; Boschi, S. Synthesis and quality control of 68Ga citrate for routine clinical PET. Nucl. Med. Commun., 2009, 30(7), 542-545.
[] [PMID: 19424101]

Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy